Investigational Drug Information for HZT-501
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the drug development status for HZT-501?
HZT-501 is an investigational drug.
There have been 4 clinical trials for HZT-501.
The most recent clinical trial was a Phase 3 trial, which was initiated on September 1st 2009.
The most common disease conditions in clinical trials are Osteoarthritis, Nociceptive Pain, and Low Back Pain. The leading clinical trial sponsors are Horizon Pharma Ireland, Ltd., Dublin Ireland and [disabled in preview].
Summary for HZT-501
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 73 |
| WIPO Patent Applications | 35 |
| Japanese Patent Applications | 11 |
| Clinical Trial Progress | Phase 3 (2009-09-01) |
| Vendors | 0 |
Recent Clinical Trials for HZT-501
| Title | Sponsor | Phase |
|---|---|---|
| Safety Study of HZT-501 in Patients Who Require Long-Term Daily Non-steroidal Anti-inflammatory Drug Treatment | Horizon Pharma Ireland, Ltd., Dublin Ireland | Phase 3 |
| Double-Blind Follow-on Safety Study of HZT-501 (Ibuprofen 800 mg/Famotidine 26.6 mg) in Subjects Who Have Completed Participation in HZ-CA-301 (NCT00450658) or HZ-CA-303 (NCT00450216) | Horizon Pharma Ireland, Ltd., Dublin Ireland | Phase 3 |
| Efficacy and Safety Study of HZT-501 in Subjects Requiring Nonsteroidal Anti-Inflammatory Drug (NSAID) Treatment | Horizon Pharma Ireland, Ltd., Dublin Ireland | Phase 3 |
Clinical Trial Summary for HZT-501
Top disease conditions for HZT-501
Top clinical trial sponsors for HZT-501
US Patents for HZT-501
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
